Acute Graft-Versus-Host Disease (GVHD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Acute Graft-Versus-Host Disease (GVHD) Market Outlook
Thelansis’s “Acute Graft-Versus-Host
Disease (GVHD) Market Outlook, Epidemiology, Competitive Landscape, and Market
Forecast Report – 2024 To 2034" covers disease overview, epidemiology,
drug utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Acute Graft-Versus-Host Disease
(GVHD) treatment modalities options for
eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Acute
Graft-Versus-Host Disease (GVHD) Overview
Acute
graft-versus-host disease (GVHD) emerges as a response from donor immune cells
targeting host tissues post-allogeneic hematopoietic stem cell transplant. It
initiates with an inflammatory cascade triggered by the preparative regimen,
leading to damage of host epithelial cells by activated donor T cells.
Approximately 35–50% of hematopoietic stem cell transplant (HSCT) recipients
experience acute GVHD, with risk factors including stem cell source, patient
age, conditioning, and GVHD prophylaxis. The severity of acute GVHD staged and
graded from 0 to IV based on organ involvement significantly impacts prognosis,
particularly in grade III/IV cases. Treatment typically involves enhancing
immunosuppression and administering methylprednisolone, which is effective in
around half of patients. If there’s no improvement within three or seven days,
salvage (second-line) immunosuppressive therapy is considered. Notably,
Ruxolitinib, an oral selective JAK1/2 inhibitor, gained FDA approval in 2019 as
the sole agent for treating steroid-refractory acute GVHD.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment